AXL and neoplasm: Furthermore, we demonstrated that the anti-tumor efficacy was markedly enhanced by co-administration of DSP-0509 with either an IDO1 inhibitor or an AXL inhibitor, although involvement of diverse immune cell except for Tregs and macrophages needs to be examined in the future study.